Aventis Pharma Limited

Aventis Pharmaceuticals Inc.

Rhone Poulenc Rorer

Christopher Hulme

Stevan Wakefield Djuric

John R Regan

Daniel Gerard McGarry

Gregory Bernard Poli

Paul Joseph Cox

David John Aldous

Kevin Joseph Moriarty

Rose Mappilakunnel Mathew

Fu-Chih Huang

Peter Charles Astles

Shelley Bower

Joseph M Salvino

George C Morton

Richard F Labaudiniere

Matthew M Morrissette

Liang Ma

Helen J Mason

Marie-Pierre Cherrier

This invention is directed to physiologically active compounds of formula (I) wherein represents a bicyclic ring system, of about 10 to about 13 ring members, in which the ring is an azaheterocycle, and the ring represents an azaheteroaryl ring, or an optionally halo substituted benzene ring; and N-oxides thereof, and pharmaceutically acceptable salts of the compounds of formula (I) and N-oxides thereof, Such compounds inhibit the production or physiological effects of TNF and inhibit cyclic AMP phosphodiesterase. The invention is also directed to pharmnaceutical compositions comprising compoundS of formula (I), their phatmaceUtical use and methods for their preparation.

Substituted azabicyclic compounds

A method for preparing a N-&lsqb;(aliphatic or aromatic)carbonyl)&rsqb;-2-aminoacetamide compound, and for preparing a cyclized compound therefrom, as well as novel resin bound intermediate compounds that are useful for preparing such compounds.

Methods for preparing N-&lsqb;(aliphatic or aromatic)carbonyl)&rsqb;-2-aminoaetamide compounds and for cyclizing such compounds

This invention is directed to certain physiologically active compounds of formula (I)

Growing community of inventors

Phoenixville, PA, United States of America

Christopher Hulme